Navigation Links
Savient Announces the Election of Robert G. Savage to its Board of Directors
Date:12/5/2012

BRIDGEWATER, N.J., Dec. 5, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that Robert (Bob) G. Savage has been elected to the Company's Board of Directors, effective December 5, 2012.

"Bob is a proven leader with an exceptional track record of success, and we are fortunate to have a pharmaceutical executive with such a wealth of experience join our Board of Directors," stated Stephen O. Jaeger, Chairman of Savient's Board of Directors.

Mr. Savage is currently President and CEO of Strategic Imagery LLC, a consulting company of which he is the principal.  Previously, Mr. Savage was Group Vice President and President of the Worldwide General Therapeutics & Inflammation Business of Pharmacia Corporation from 2002 until its acquisition by Pfizer, Inc. in 2003.  Prior to that role, he held several senior positions with Johnson & Johnson, including Worldwide Chairman of the Pharmaceuticals Group, Company Group Chairman for the North American pharmaceuticals business, President of Ortho-McNeil Pharmaceuticals and Vice President of Sales and Marketing. Earlier in his career, he served in a variety of senior marketing, operations, business development and strategic planning positions for Hoffmann-La Roche, Inc.  Mr. Savage currently serves as a director of EpiCept Corporation, Nuovo Biologics and The Medicines Company.  Mr. Savage received a B.S. in Biology from Upsala College and an M.B.A. from Rutgers University.

"Given Bob's extensive experience in domestic and international marketing, business development and operations, we are confident that he will immediately prove to be an invaluable addition to the board and as an advisor to our senior management team especially in light of the anticipated approval and launch of KRYSTEXXA® in the EU," said Lou Ferrari, President and Chief Executi
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Savient Pharmaceuticals Reports Third Quarter 2012 Financial Results
2. Savient Pharmaceuticals to Present at the 6th Annual Imperial Capital Global Opportunities Conference
3. Savient Pharmaceuticals to Present at the Rodman & Renshaw 14th Annual Healthcare Conference
4. Savient Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Growth Conference
5. Savient Pharmaceuticals Adopts Stockholder Rights Plan
6. Savient Pharmaceuticals Receives Favorable Decision In Tang Capital Litigation
7. Savient Pharmaceuticals to Hold Second Quarter 2012 Financial Results Conference Call on Wednesday, August 8, 2012
8. Savient Pharmaceuticals Announces CEO Appointment and Reorganization Plan to Drive Long-Term Growth
9. Savient Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
10. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
11. Harrington Discovery Institute at University Hospitals Case Medical Center Announces Grant Funding to Physician-Scientists at Major Academic Medical Centers to Support New Drug Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... , July 28, 2015 On the afternoon ... parent company of CPI International, Inc. (CPI), plans to ... July 3, 2015 with the Securities and Exchange Commission ... for the quarter.  At 11 a.m. (EDT) on Wednesday, ... call in conjunction with this release that will be ...
(Date:7/28/2015)... -- Research and Markets ( ... "Craniomaxillofacial Implants Market - Global Industry Analysis, ... 2022" report to their offering. ... the current and future prospects of the global ... the global market due to increasing facial deformities ...
(Date:7/28/2015)... 28, 2015 At the 2015 ... Association recognized 15 winners in the categories of ... across multiple vertical markets. ContextMedia:Health proudly took ... for its success with its first-to-market Patient ... ContextMedia:Health, the leading provider of digital solutions ...
Breaking Medicine Technology:CPI International To Announce Third Quarter 2015 Financial Results 2Global Craniomaxillofacial Implants (Plate and Screw Fixator Systems, Bone Graft Substitutes, Distraction Systems, and TMJ Replacement Devices) Market Analysis 2014-2022 2ContextMedia:Health Receives Top Award at the ICX Association Excellence Awards 2
... SPRING, Md., Oct. 24, 2011 The U.S. ... generic versions of Zyprexa (olanzapine tablets) and Zyprexa ... and bipolar disorder. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ... and disabling brain disorder. About 1 percent of ...
... BRANFORD, Conn., Oct. 24, 2011 Clarient, a ... signed a definitive agreement to provide pharma services ... pharma clients.  By implementing HistoRx,s AQUA technology in ... their complementary capabilities to serve pharma companies, growing ...
Cached Medicine Technology:FDA Approves First Generic Olanzapine to Treat Schizophrenia, Bipolar Disorder 2FDA Approves First Generic Olanzapine to Treat Schizophrenia, Bipolar Disorder 3Clarient Joins the HistoRx® Clinical Trials Network: First Commercial Lab to Provide Aqua® Technology for Clinical Trials 2
(Date:7/28/2015)... ... July 28, 2015 , ... Dr. Aziz Ahmad recently gave a talk on ... noon to 1 p.m. Tuesday, June 23, at the Gulf Coast Regional Medical Center ... is board-certified in colorectal surgery and has more than 35 years of experience in ...
(Date:7/28/2015)... ... July 28, 2015 , ... Healthpointe ’s Cosmetic Laser ... skin to a smooth state, and reduces the appearance of fine lines and wrinkles. ... FDA-approved injectable gel to instantly add volume to your cheek area to correct age-related ...
(Date:7/28/2015)... ... ... to WFTV on July 15th heroin overdose rates have increased by 270 ... statistic Orlando suffers at least one death weekly as a direct result of a ... officials are struggling to keep apace with its distribution. Officers rely on inside information ...
(Date:7/28/2015)... , ... July 28, 2015 , ... ... targeted biologics and biologic-device combination products for the treatment of bone disorders and ... U.S. Patent No. 9,062,300 entitled "Fusion Proteins of Collagen Binding-Domain and Parathyroid Hormone". ...
(Date:7/28/2015)... , ... July 28, 2015 , ... Women fear developing ... reason is that cancer, heart attack, and stroke are treatable, but there is little ... can do is to take part in a clinical trial, reports the July 2015 ...
Breaking Medicine News(10 mins):Health News:Dr. Aziz Ahmad Delivers Talk at Gulf Coast Medical Center 2Health News:Healthpointe’s Cosmetic Laser Institute Now Providing Juvéderm Voluma XC in Anaheim 2Health News:Healthpointe’s Cosmetic Laser Institute Now Providing Juvéderm Voluma XC in Anaheim 3Health News:Heroin Overdose Deaths Increase by 270 Percent, Orlando Takes the Lead 2Health News:Heroin Overdose Deaths Increase by 270 Percent, Orlando Takes the Lead 3Health News:BiologicsMD, Inc. Announces Additional US Patent Issuance Covering Company’s Pipeline of Targeted Therapies 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 3
... Cardiovascular disease (CVD) death rates are declining, but CVD ... the United States, and risk factor control remains a ... from the American Heart Associations Heart Disease and Stroke ... available in the Dec. 17 online issue of Circulation: ...
... on an enzyme that is critical to the process ... target of antibacterial and anticancer drugs. Researchers with the ... Lab) and the University of California (UC) at Berkeley ... DNA-bound Type II topoisomerase (topo II) that is responsible ...
... for Dealing With Elderly Holiday Blues Offered by One of the ... ... of the country,s senior,healthcare experts from the world-renowned Los Angeles Jewish ... group,particularly vulnerable to the blues at this time of year -- ...
... CAMPAIGN "KICK ONE, PICK ONE" ENCOURAGING ... AND SPEND TIME TOGETHER, NEW YORK, Dec. 20 ... Nite announces the launch of "Kick One, Pick One",(KOPO), the ... fit and spend more time together. Bowing Jan. 1, KOPO ...
... children , , THURSDAY, Dec. 20 (HealthDay News) -- Holiday toys ... are threatening to cause more worry than joy. , Millions ... months by toy companies, many because they were decorated with ... Barbie, and Thomas the Tank Engine, among others. , The ...
... were given Nobel Direct dental implants, the risk of the ... at the Sahlgrenska Academy in Sweden shows that eight per ... was launched in 2004 by Nobel Biocare AB. The implants ... directly into the jawbone without having to first lift up ...
Cached Medicine News:Health News:Cardiovascular disease death rates decline, but risk factors still exact heavy toll 2Health News:Cardiovascular disease death rates decline, but risk factors still exact heavy toll 3Health News:Cardiovascular disease death rates decline, but risk factors still exact heavy toll 4Health News:Cardiovascular disease death rates decline, but risk factors still exact heavy toll 5Health News:First look at an enzyme target for antibacterial and cancer drugs 2Health News:First look at an enzyme target for antibacterial and cancer drugs 3Health News:First look at an enzyme target for antibacterial and cancer drugs 4Health News:It's Not Just About the Children 2Health News:It's Not Just About the Children 3Health News:Nick at Nite Asks Families to Kick a Bad Habit, Pick a Good One in 2008 2Health News:Nick at Nite Asks Families to Kick a Bad Habit, Pick a Good One in 2008 3Health News:Make Safe Toys Your Holiday Priority 2Health News:Make Safe Toys Your Holiday Priority 3Health News:Gloomy forecast for Nobel Direct after 3 years 2
... The ndigo OPTIMA Laser System is designed ... ablation using a near infrared laser source. ... the laser delivers a controlled level of ... to a temperature range where tissue necrosis ...
... a device intended for highly accurate measurements ... single most important metric for the diagnosis ... discovered in a large, randomized, five-year National ... mid-2002, the patients central cornea thickness (CCT) ...
Rapid Test Kit...
... Information System) is an open architecture system ... platform designed to communicate and manage patient ... be expanded in various ways, as NAVIS ... but also to fundus cameras and ophthalmic ...
Medicine Products: